CLINICAL RESEARCH
Clinical trial registrations
Explore the study designs, treatment combinations and clinical questions being investigated across the PRaG research program. Follow each registry link for recruitment information and study details.
PRaG · SFRTNCT07342322
A Prospective, Multicenter, Open-label, Single-arm Phase II Clinical Study Evaluating the Efficacy and Safety of Spatially Fractionated Radiotherapy Combined With the PraG Strategy for the Treatment of Soft Tissue Sarcoma
A Guangxi-sponsored study of spatially fractionated radiotherapy and a PRaG-based strategy for soft tissue sarcoma.
First posted: Jan 15, 2026 · Registry updated: Jan 15, 2026Sponsor: First Affiliated Hospital of Guangxi Medical UniversityPRaG + cetuximab βNCT07327411
Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors
Investigates cetuximab beta with PRaG in EGFR-positive refractory solid tumors.
First posted: Jan 8, 2026 · Registry updated: Jan 8, 2026Sponsor: Second Affiliated Hospital of Soochow UniversityPRaG 10.0NCT07267234
PRaG-1 Plus PRaG Therapy in Advanced Solid Tumors: A Prospective Clinical Trial (PRaG 10.0)
Investigates PRaG-1 cordycepin tablets added to a PRaG treatment program.
First posted: Dec 5, 2025 · Registry updated: Dec 5, 2025Sponsor: Second Affiliated Hospital of Soochow UniversityNeoPRAGNCT06345599
PRaG Therapy in Combination With Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) (NeoPRAG Study)
Evaluates a PRaG-based neoadjuvant strategy with chemotherapy in locally advanced pancreatic cancer.
First posted: Apr 3, 2024 · Registry updated: Apr 3, 2024Sponsor: Second Affiliated Hospital of Soochow UniversityPRaG 9.0NCT06112041
The Prospective Clinical Study of Precision PRaG Therapy in Elderly Patients With Advanced Solid Malignant Tumors (PRaG9.0)
A prospective program focusing on older adults with advanced solid tumors.
First posted: Nov 1, 2023 · Registry updated: Nov 1, 2023Sponsor: Second Affiliated Hospital of Soochow UniversityPRaG 2.0ENCT06047860
A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer
Explores recombinant human endostatin alongside PRaG in refractory lung cancer.
First posted: Sep 21, 2023 · Registry updated: Sep 21, 2023Sponsor: Second Affiliated Hospital of Soochow UniversityPRaG 5.0NCT05790447
Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors
Evaluates thymalfasin adjustment with a PRaG-based regimen.
First posted: Mar 30, 2023 · Registry updated: Mar 30, 2023Sponsor: Second Affiliated Hospital of Soochow UniversityPRaG 6.0NCT05603013
Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)
Examines metronomic vinorelbine added to radiotherapy, checkpoint inhibition and cytokines.
First posted: Nov 2, 2022 · Registry updated: Nov 2, 2022Sponsor: Second Affiliated Hospital of Soochow UniversityPRaG rechallengeNCT05530200
PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors.
Explores a PRaG-based approach after resistance to checkpoint inhibitors.
First posted: Sep 7, 2022 · Registry updated: Sep 7, 2022Sponsor: Second Affiliated Hospital of Soochow UniversityPRaG 4.0PNCT05501340
PD-1 Inhibitor Intraperitoneal Perfusion Combined With PRaG Therapy for Malignant Ascites
Investigates intraperitoneal PD-1 inhibitor delivery together with PRaG for malignant ascites.
First posted: Aug 15, 2022 · Registry updated: Aug 15, 2022Sponsor: Second Affiliated Hospital of Soochow UniversityPRaG + denosumabNCT05435768
PraG With RANKL Inhibitor for the Treatment of Advanced Multiple Metastatic Solid Tumors
Evaluates adding denosumab and different treatment sequences to a PRaG-based strategy.
First posted: Jun 28, 2022 · Registry updated: Aug 18, 2022Sponsor: Second Affiliated Hospital of Soochow UniversityPRaG 3.0NCT05115500
ADC Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of HER-2 Positive Advanced Solid Tumors(PRaG3.0)
Studies the combination of disitamab vedotin with a PRaG-based regimen in HER2-expressing tumors.
First posted: Nov 10, 2021 · Registry updated: Nov 10, 2021Sponsor: Second Affiliated Hospital of Soochow UniversityPRaG 2.0NCT04892498
Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)
Evaluates the addition of sequential IL-2 to a radiotherapy, checkpoint-inhibitor and GM-CSF regimen.
First posted: May 19, 2021 · Registry updated: Aug 9, 2022Sponsor: Second Affiliated Hospital of Soochow UniversitySWORDNCT04106180
SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC
An independent related trial for advanced non-small cell lung cancer; not a PRaG-series registration.
First posted: Sep 26, 2019 · Registry updated: Sep 26, 2019Sponsor: Fudan University